

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 2, 2026

Cancer Treatment Response gene signature DataBase

RRID:SCR_027950

Type: Tool

Proper Citation

Cancer Treatment Response gene signature DataBase (RRID:SCR_027950)

Resource Information

URL: <http://ctrdb.ncpsb.org.cn/>

Proper Citation: Cancer Treatment Response gene signature DataBase (RRID:SCR_027950)

Description: Data resource for clinical transcriptomes with cancer treatment response, and meanwhile supports various data analysis functions, providing insights into the molecular determinants of drug resistance. CTR-DB 2.0 is updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers.

Abbreviations: CTR_DB

Synonyms: , CTR-DB 1.0, CTR-DB 2.0

Resource Type: data or information resource, database

Defining Citation: [PMID:39494527](#)

Keywords: clinical transcriptomes, cancer treatment response, primary drug resistance, predictive biomarkers,

Funding: National Key Research and Development Program of China ; National Natural Science Foundation of China

Availability: Free, Freely available,

Resource Name: Cancer Treatment Response gene signature DataBase

Resource ID: SCR_027950

Record Creation Time: 20260210T055447+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Treatment Response gene signature DataBase.

No alerts have been found for Cancer Treatment Response gene signature DataBase.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Deng R, et al. (2026) Integrated multi-omics analysis and functional validation reveal the role of TRIM2 as a potential novel biomarker in breast cancer. Breast cancer research : BCR, 28(1).

Bai X, et al. (2026) Pan-cancer expression, methylation, and prognostic significance of ?7 nicotinic acetylcholine receptor in tumor immunology. Biochemistry and biophysics reports, 47, 102649.

Tian T, et al. (2025) DBI as a Novel Immunotherapeutic Candidate in Colorectal Cancer: Dissecting Genetic Risk and the Immune Landscape via GWAS, eQTL, and pQTL. Biomedicines, 13(5).

Liu R, et al. (2025) Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis. iScience, 28(12), 113908.

Wang YJ, et al. (2023) Prostaglandin F2? synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2?-dependent and F2?-independent mechanism. World journal of gastroenterology, 29(39), 5452.